Fungal Diseases (Field Manual of Wildlife Diseases)

M. Friend

Abstract:

What problem does this paper attempt to address?

Clinical analysis of acute pulmonary embolism in 49 cases

LI Li,LI Ling,LIU Huiping,李黎,李凌,刘惠萍

DOI: https://doi.org/10.3760/cma.j.issn.1674-4756.2006.22.003

2006-01-01

Abstract:Objective To elevate recognition of pulmonary embolism(PE)by analysing its clinical characteristic.Methods Risk factors,clinical presentation,auxiliary examination and treatment of 49 patients with established acute pulmonary embolism were analyzed retrospectively.Results PE has a wide range of clinical presentation.The most common symptoms are dyspnoea and chest pain.In all 49 patients with pulmonary embolism,9 cases had typical findings S_ⅠQ_ⅢT_Ⅲ on ECG,30 cases had found deep vein thrombosis by ultrasonic cardiogram.82.9% had D-dimer >500 μg/L.91.4% had abnomal pulmonary perfusion/ventilation imaging,the spiral computed tomography(sCT)showed the positive rate of PE was 87.5%.Twenty patients received thrombolytic therapy and 19 cases had recovered or improved.Conclusion Because the symptoms of PE are unspecific,we shoud do auxiliary examination in suspected patients rationally.Thrombolytic and anticoagulant therapy can improve the survival rate of patients with pulmonary embolism.
Pulmonary embolism: the diagnosis, risk-stratification, treatment and disposition of emergency department patients

Daniel Corrigan,Christiana Prucnal,Christopher Kabrhel

DOI: https://doi.org/10.15441/ceem.16.146

2016-09-30

Clinical and Experimental Emergency Medicine

Abstract:The diagnosis or exclusion of pulmonary embolism (PE) remains challenging for emergency physicians. Symptoms can be vague or non-existent, and the clinical presentation shares features with many other common diagnoses. Diagnostic testing is complicated, as biomarkers, like the D-dimer, are frequently false positive, and imaging, like computed tomography pulmonary angiography, carries risks of radiation and contrast dye exposure. It is therefore incumbent on emergency physicians to be both vigilant and thoughtful about this diagnosis. In recent years, several advances in treatment have also emerged. Novel, direct-acting oral anticoagulants make the outpatient treatment of low risk PE easier than before. However, the spectrum of PE severity varies widely, so emergency physicians must be able to risk-stratify patients to ensure the appropriate disposition. Finally, PE response teams have been developed to facilitate rapid access to advanced therapies (e.g., catheter directed thrombolysis) for patients with high-risk PE. This review will discuss the clinical challenges of PE diagnosis, risk stratification and treatment that emergency physicians face every day.
Risk Stratification and Management of Intermediate- and High-Risk Pulmonary Embolism

Sanaullah Mojaddedi,Javairia Jamil,Daniel Bishev,Kobina Essilfie-Quaye,Islam Y. Elgendy

DOI: https://doi.org/10.3390/jcm13185583

IF: 3.9

2024-09-21

Journal of Clinical Medicine

Abstract:Acute pulmonary embolism (PE) is a leading cause of mortality. Not only is PE associated with short-term mortality, but up to ~20% of patients might suffer from long-term consequences such as post-PE syndrome and chronic thromboembolic pulmonary hypertension. Current risk stratification tools poorly predict those who are at risk for short-term deterioration and those who develop long-term consequences. Traditionally, systemic thrombolysis has been considered the first-line therapy for patients with high-risk PE without contraindications; however, it comes with the risk of major bleeding (notably intracranial hemorrhage). The use of catheter-directed interventions (embolectomy or thrombolysis) has been increasing owing to their low bleeding risk; however, randomized trial data supporting their efficacy in improving clinical outcomes are limited. In this review, we highlight the evidence supporting the available advanced therapies for high- and intermediate-risk PE and summarize the ongoing trials which are evaluating these therapies.

medicine, general & internal
Risk Stratification and Management of Intermediate-Risk Acute Pulmonary Embolism

Nichole Brunton,Robert McBane,Ana I. Casanegra,Damon E. Houghton,Dinu V. Balanescu,Sumera Ahmad,Sean Caples,Arashk Motiei,Stanislav Henkin

DOI: https://doi.org/10.3390/jcm13010257

IF: 3.9

2024-01-02

Journal of Clinical Medicine

Abstract:Pulmonary embolism (PE) is the third most common cause of cardiovascular death and necessitates prompt, accurate risk assessment at initial diagnosis to guide treatment and reduce associated mortality. Intermediate-risk PE, defined as the presence of right ventricular (RV) dysfunction in the absence of hemodynamic compromise, carries a significant risk for adverse clinical outcomes and represents a unique diagnostic challenge. While small clinical trials have evaluated advanced treatment strategies beyond standard anticoagulation, such as thrombolytic or endovascular therapy, there remains continued debate on the optimal care for this patient population. Here, we review the most recent risk stratification models, highlighting differences between prediction scores and their limitations, and discuss the utility of serologic biomarkers and imaging modalities to detect right ventricular dysfunction. Additionally, we examine current treatment recommendations including anticoagulation strategies, use of thrombolytics at full and reduced doses, and utilization of invasive treatment options. Current knowledge gaps and ongoing studies are highlighted.

medicine, general & internal
Decoding Pulmonary Embolism: Pathophysiology, Diagnosis, and Treatment

Miriam Peracaula,Laura Sebastian,Iria Francisco,Marc Bonnin Vilaplana,Diego A. Rodríguez-Chiaradía,Olga Tura-Ceide

DOI: https://doi.org/10.3390/biomedicines12091936

IF: 4.757

2024-08-25

Biomedicines

Abstract:Pulmonary Embolism (PE) is a life-threatening condition initiated by the presence of blood clots in the pulmonary arteries, leading to severe morbidity and mortality. Underlying mechanisms involve endothelial dysfunction, including impaired blood flow regulation, a pro-thrombotic state, inflammation, heightened oxidative stress, and altered vascular remodeling. These mechanisms contribute to vascular diseases stemming from PE, such as recurrent thromboembolism, chronic thromboembolic pulmonary hypertension, post-thrombotic syndrome, right heart failure, and cardiogenic shock. Detailing key risk factors and utilizing hemodynamic stability-based categorization, the review aims for precise risk stratification by applying established diagnostic tools and scoring systems. This article explores both conventional and emerging biomarkers as potential diagnostic tools. Additionally, by synthesizing existing knowledge, it provides a comprehensive outlook of the current enhanced PE management and preventive strategies. The conclusion underscores the need for future research to improve diagnostic accuracy and therapeutic effectiveness in PE.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
Acute Pulmonary Embolism: A Review

Yonathan Freund,Fleur Cohen-Aubart,Ben Bloom

DOI: https://doi.org/10.1001/jama.2022.16815

IF: 11.816

2022-10-04

JAMA

Abstract:Importance: Pulmonary embolism (PE) is characterized by occlusion of blood flow in a pulmonary artery, typically due to a thrombus that travels from a vein in a lower limb. The incidence of PE is approximately 60 to 120 per 100 000 people per year. Approximately 60 000 to 100 000 patients die from PE each year in the US. Observations: PE should be considered in patients presenting with acute chest pain, shortness of breath, or syncope. The diagnosis is determined by chest imaging. In patients with a systolic blood pressure of at least 90 mm Hg, the following 3 steps can be used to evaluate a patient with possible PE: assessment of the clinical probability of PE, D-dimer testing if indicated, and chest imaging if indicated. The clinical probability of PE can be assessed using a structured score or using clinical gestalt. In patients with a probability of PE that is less than 15%, the presence of 8 clinical characteristics (age <50 years, heart rate <100/min, an oxygen saturation level of > 94%, no recent surgery or trauma, no prior venous thromboembolism event, no hemoptysis, no unilateral leg swelling, and no estrogen use) identifies patients at very low risk of PE in whom no further testing is needed. In patients with low or intermediate clinical probability, a D-dimer level of less than 500 ng/mL is associated with a posttest probability of PE less than 1.85%. In these patients, PE can be excluded without chest imaging. A further refinement of D-dimer threshold is possible in patients aged 50 years and older, and in patients with a low likelihood of PE. Patients with a high probability of PE (ie, >40% probability) should undergo chest imaging, and D-dimer testing is not necessary. In patients with PE and a systolic blood pressure of 90 mm Hg or higher, compared with heparin combined with a vitamin K antagonist such as warfarin followed by warfarin alone, direct oral anticoagulants such as apixaban, edoxaban, rivaroxaban, or dabigatran, are noninferior for treating PE and have a 0.6% lower rate of bleeding. In patients with PE and systolic blood pressure lower than 90 mm Hg, systemic thrombolysis is recommended and is associated with an 1.6% absolute reduction of mortality (from 3.9% to 2.3%). Conclusions and relevance: In the US, PE affects approximately 370 000 patients per year and may cause approximately 60 000 to 100 000 deaths per year. First-line therapy consists of direct oral anticoagulants such as apixaban, edoxaban, rivaroxaban, or dabigatran, with thrombolysis reserved for patients with systolic blood pressure lower than 90 mm Hg.
Presentation, Management and Outcomes of Pediatric Pulmonary Embolus: A Retrospective Review

Alexandra Lucas,Rachel Rosovsky,Maureen Clark,Eric Grabowski,Phoebe Yager

DOI: https://doi.org/10.1097/PEC.0000000000002417

2022-02-01

Abstract:Objectives: To review the presentation, management, and outcomes of pediatric pulmonary embolism (PE) patients treated at a single institution over 10 years to determine whether laboratory findings and clinical presentation predict disease severity. Methods: We performed a retrospective chart review of patients treated for PE in a 14-bed pediatric intensive care unit from January 1, 2008, to December 31, 2018. Associations between clot burden and disease severity, clinical risk factors (body mass index, recent hospitalization, estrogen use), clinical presentation (heart rate, oxygen saturation), and laboratory values (white blood cell count, D-Dimer, troponin, proBNP) were performed using Student t test, χ2 tests, and 1-way analysis of variance. Patients were risk stratified by American Heart Association guidelines. Results: Eighteen (72%) patients (girls) were treated for PE. Common risk factors included recent hospitalization (67%) and oral contraceptives (62%). Risk factors, clinical presentation (including hypoxemia and tachypnea), and laboratory studies did not correlate with disease severity or clot burden. Electrocardiogram and radiographic findings were non-specific. Computer tomography pulmonary angiography (CTPA) was required to diagnose 94%. Sixteen received unfractionated heparin, and 5 required additional intervention. Risk factors, clinical features, and laboratory studies did not predict who required intervention. Conclusions: Of 18 pediatric patients treated for PE at a single institution over 10 years, vital signs and laboratory data did not predict disease severity or clot burden, and CTPA was required for diagnosis in all but 1. Emergency room providers must have a high index of suspicion for diagnosis and cannot be reassured by normal electrocardiogram or plain film findings. At a time when pediatric providers are under pressure to minimize unnecessary radiation exposure, this lack of correlation of clinical presentation and laboratory findings highlights the importance of considering CTPA when PE is suspected.
Patients perceptions of information about risks at cardiac surgery.

B. Ivarsson,S. Larsson,C. Lührs,T. Sjöberg

DOI: https://doi.org/10.1016/J.PEC.2007.01.014

IF: 3.467

2007-07-01

Patient Education and Counseling

Abstract:
Acute Pulmonary Embolism: Evidence, Innovation, and Horizons

Stanislav Henkin,Francisco Ujueta,Alyssa Sato,Gregory Piazza

DOI: https://doi.org/10.1007/s11886-024-02128-0

Abstract:Purpose of review: Pulmonary embolism (PE) is the third most common cause of cardiovascular morbidity and mortality. The goal of this review is to discuss the most up-to-date literature on epidemiology, diagnosis, risk stratification, and management of acute PE. Recent findings: Despite an increase in annual incidence rate of PE in the United States and development of multiple advanced therapies for treatment of acute PE, PE-related mortality is not consistently decreasing across populations. Although multiple risk stratification schemes have been developed, it is still unclear which advanced therapy should be used for the individual patient and optimal timing. Fortunately, multiple randomized clinical trials are underway to answer these questions. Nevertheless, up to 50% of patients have persistent reduced quality of life 6 months after acute PE, termed post-PE syndrome. Despite advances in therapeutic options for management of acute PE, many questions remain unanswered, including optimal risk stratification and management of acute PE.
The diagnosis of Blastocystis hominis cysts in human faeces.

V. Zaman

DOI: https://doi.org/10.1016/S0163-4453(96)92662-6

IF: 28.2

1996-07-01

Journal of Infection

Abstract:
Comparison of costs of percutaneous transluminal coronary angioplasty and coronary bypass surgery for patients with angina pectoris.

M. Brand,C. Halem,F.Den Van Brink,P. D. Feyter,P. Serruys,H. Suryapranata,K. Meeter,E. Bos,F. J. Dalen

DOI: https://doi.org/10.1093/OXFORDJOURNALS.EURHEARTJ.A059792

IF: 39.3

1990-08-01

European Heart Journal

Abstract:To determine the costs of a procedure, the total costs of the department that provides the service must be considered and, in addition, the direct cost of the specific procedure. Applying this principle to the cost accounting of angioplasty and bypass surgery results in a direct, i.e. procedural, cost, including the initial hospital stay, of respectively 8694 Dfl and 20,987 Dfl. A review of the follow-up data for the first year after the original intervention revealed a 2% reintervention rate for bypass surgery, while this percentage was 29% for angioplasty. Adding the first year costs involved with reinterventions to the procedural costs results in a 1-year cost of angioplasty and bypass operation of 13,625 Dfl and 21,363 Dfl, respectively. It is concluded that because of reinterventions in the first year, a mark up of 57% on the procedural cost of angioplasty must be added to cover 1-year costs, while for bypass surgery this is only 1%. Nevertheless, the 1-year cost for angioplasty is still 36% less than for bypass surgery. As reinterventions after PTCA may stay considerably higher than for CABG for several years, the mark-up percentages will be substantially higher for longer time spans. This may tend to equalize the total costs of PTCA and CABG over time spans of perhaps 5-8 years. Sufficient data are not available to verify this statement. Clinicians must realize that choosing the most appropriate procedure is not only a matter of medical assessment but also a matter of cost effectiveness. CABG can be seen as an 'investment decision' while PTCA tends to become a decision with characteristics of 'maintenance planning'!
Emergency department diagnosis and management of acute pulmonary embolism

Jesse O. Wrenn,Christopher Kabrhel

DOI: https://doi.org/10.1111/bjh.19725

2024-08-27

British Journal of Haematology

Abstract:Despite advances in clinical decision support, the diagnosis, prognostic risk stratification, treatment and disposition of emergency department patients with pulmonary embolism remain challenging. Diagnostic risk stratification and D‐dimer can decrease unnecessary exposure to radiation and intravenous contrast; however, D‐dimer is elevated in many conditions including normal pregnancy, so imaging is often indicated. Prognostic risk stratification tools inform treatment decisions across the risk spectrum, including identifying low‐risk patients with pulmonary embolism who can safely be treated at home. For hospitalized patients, alternatives to unfractionated heparin improve time to therapeutic anticoagulation and reduce bleeding risk. Summary Despite advances in clinical decision support, the diagnosis, prognostic risk stratification, treatment and disposition of emergency department patients with pulmonary embolism remain challenging. The use of diagnostic risk stratification tools and D‐dimer can decrease unnecessary exposure to radiation and intravenous contrast; however, D‐dimer is elevated in many conditions including normal pregnancy, so imaging is often indicated. Once diagnosed, prognostic risk stratification tools can inform treatment decisions across the risk spectrum, including identifying low‐risk patients with pulmonary embolism who can safely be treated at home. For patients requiring hospitalization, alternatives to unfractionated heparin can improve time to therapeutic anticoagulation and reduce treatment‐related bleeding risk.

hematology
Epidemiology, Etiology, and Pathophysiology of Pulmonary Embolism

Catherine R Glazier,Frank A Baciewicz Jr

DOI: https://doi.org/10.1055/s-0044-1785487

2024-04-12

Abstract:Over the last 20 years, there has been a progressive increase in the incidence of pulmonary embolism (PE) diagnosis in the United States, Europe, and Australia. Increased use of computed tomography pulmonary angiography has likely contributed in part to this rising incidence. However, it is pertinent to note that the burden of comorbidities associated with PE, such as malignancy, obesity, and advanced age, has also increased over the past 20 years. Time-trend analysis in North American, European, and Asian populations suggests that mortality rates associated with PE have been declining. The reported improved survival rates in PE over the past 20 years are likely, at least in part, to be the result of better adherence to guidelines, improved risk stratification, and enhanced treatment. Factors contributing to the development of venous thromboembolism (VTE) include stasis of blood, hypercoagulability, endothelial injury, and inflammation. In 70 to 80% of cases of PE, the thrombi embolizes from the proximal deep veins of the lower extremities and pelvis. Strong risk factors for VTE include lower extremity fractures and surgeries, major trauma, and hospitalization within the previous 3 months for acute myocardial infarction or heart failure with atrial fibrillation. Acute PE causes several pathophysiological responses including hypoxemia and right ventricle (RV) failure. The latter is a result of pulmonary artery occlusion and associated vasoconstriction. Hemodynamic compromise from RV failure is the principal cause of poor outcome in patients with acute PE.
The Clinical Analysis and Treatment of Acute Pulmonary Embolism

GE Qiang,ZHANG Hong

DOI: https://doi.org/10.3969/j.issn.1004-5775.2007.04.031

2007-01-01

Abstract:Objective To analyze the clinical manifestation of pulmonary embolism(PE),and to design diagnostic procedures,and clinical management for PE.Methods We retrospectively analyzed the clinical data of 48 patients with PE.Results Total misdiagnosis rate of the first consultation in 48 acute PE patients was 72.9%,79.2% of those had hypoxemia and/or hypocapnemia,91.7% of those showed D-dimmer positive(500 μg/L),85.4% of those have typical changes on UCG,87.5% patients showed filling-defect at or above pulmonary segmental artery level.Conclusion Misdiagnosis the of PE is high,Doctors in emergency department should have a high sense of diagnosis to PE,to set up the Green Path for PE is urgent.
A Silent Fatal Presentation of Pulmonary Embolism: Reflection and Discussion.

Qian Zhang,Zain U. Abideen,Khine S. Shan,Thomas Yoon,Muhammad Farooq

DOI: https://doi.org/10.7759/cureus.8813

2020-01-01

Cureus

Abstract:Acute pulmonary embolism is a common medical condition that clinicians face in practice. It is important to have a prompt diagnosis with proper management as it is associated with high morbidity and mortality. However, a timely diagnosis is often difficult to obtain especially when the presenting symptoms are atypical, but the consequence could be fatal. We present an 80-year-old gentleman who presented with a near-syncope episode who subsequently was found to have acute extensive bilateral pulmonary embolisms after a code blue event.
Low Risk Meets High Stakes: Unraveling the Mystery of Low D-dimer Pulmonary Embolism

Sadat Kasanga,Abdallah Khashan,Ahsan Salik,Ahmed M Aboshehata,Sebastian Casillas,Mohammed Islam

DOI: https://doi.org/10.7759/cureus.51045

2023-12-24

Cureus

Abstract:Pulmonary embolisms (PEs) are potentially life-threatening emergencies that carry significant morbidity and mortality. Advances in treatment options and the safety of existing procedures have effectively reduced the long-term and short-term effects of the condition. Therefore, it is important to make an early diagnosis so that treatment options can be thoroughly explored. The D-dimer is an important tool in the early diagnosis of PEs. It is especially useful in ruling out the diagnosis in patients with a low to moderate suspicion of the disease. We present a case of a 22-year-old male who presented with exertional dyspnea, congestion, and rhinorrhea for one day and was noted to have persistent hypoxia and tachycardia. The influenza test was positive, and he was started on oseltamivir. Due to persistent hypoxia, a CT pulmonary angiogram was ordered and revealed filling defects in the left lower lobe segmental vessels suggestive of PE, as well as multifocal multilobar bilateral ground-glass opacities. He was initially treated with a heparin drip and subsequently switched to eliquis. After a significant improvement in his hypoxia, he was discharged home for outpatient follow-up, including a hypercoagulable workup. This case demonstrates that despite the usefulness of the D-dimer as a diagnostic tool for PEs, it cannot solely or fully replace the full gamut of screening tools used to determine the risk of PE. Although rare, false-negative scores do occur; therefore, the tool should always be used in conjunction with other scoring systems, physician gestalt, and within the specific clinical context.
Pulmonary Embolism: An Update Based on the Revised AWMF-S2k Guideline

Christian F. Opitz,F. Joachim Meyer

DOI: https://doi.org/10.1055/s-0044-1779011

2024-05-01

Hämostaseologie

Abstract:Pulmonary embolism (PE) is the third most common acute cardiovascular disease. The risk of PE increases with age and mortality is high. Patients are stratified into hemodynamically stable versus unstable patients, as this has important implications for diagnosis and therapy. Since clinical signs and symptoms of acute PE are nonspecific, the clinical likelihood of PE is estimated to guide diagnostic pathways. D-dimer testing is performed in hemodynamically stable patients with low or intermediate probability of PE and the visualization of thromboembolism and its sequelae is commonly achieved with computed tomography pulmonary angiography (CTPA), supplemented by ultrasound techniques. With confirmed PE, another risk stratification estimates disease severity and defines intensity and setting of the ensuing treatment. The therapeutic spectrum ranges from outpatient treatment with initial oral anticoagulation to thrombolytic or interventional treatment in the intensive care unit or catheterization laboratory. In single cases, even acute surgical thrombectomy is attempted. Received: 17 September 2023 Accepted: 14 December 2023 Article published online: 30 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

hematology
Advances in the diagnosis of acute pulmonary embolism

Ella Ishaaya,Victor F. Tapson

DOI: https://doi.org/10.12688/f1000research.21347.1

2020-01-24

F1000Research

Abstract:Venous thromboembolism is a common disease which remains underdiagnosed because of nonspecific presentations which can range from asymptomatic incidental imaging findings to sudden death. Symptoms can overlap with comorbid cardiopulmonary disease, and risk factors that offer clues to the clinician are not always present. The diagnostic approach can vary depending on the specific clinical presentation, but ruling in the diagnosis nearly always depends on lung imaging. Overuse of diagnostic testing is another recognized problem; a cautious, evidence-based approach is required, although physician gestalt must be acknowledged. The following review offers an approach to the diagnosis of acute pulmonary embolism based on the assessment of symptoms, signs, risk factors, laboratory findings, and imaging studies.
Systematic review and meta-analysis of outcomes in patients with suspected pulmonary embolism

Parth Patel,Payal Patel,Meha Bhatt,Cody Braun,Housne Begum,Robby Nieuwlaat,Rasha Khatib,Carolina C. Martins,Yuan Zhang,Itziar Etxeandia-Ikobaltzeta,Jamie Varghese,Hani Alturkmani,Waled Bahaj,Mariam Baig,Rohan Kehar,Ahmad Mustafa,Rakesh Ponnapureddy,Anchal Sethi,Merrill Thomas,David Wooldridge,Wendy Lim,Shannon M. Bates,Eddy Lang,Grégoire Le Gal,Linda B. Haramati,Jeffrey Kline,Marc Righini,Wojtek Wiercioch,Holger Schünemann,Reem A. Mustafa

DOI: https://doi.org/10.1182/bloodadvances.2020002398

IF: 7.642

2021-04-26

Blood Advances

Abstract:Abstract Prompt evaluation and therapeutic intervention of suspected pulmonary embolism (PE) are of paramount importance for improvement in outcomes. We systematically reviewed outcomes in patients with suspected PE, including mortality, incidence of recurrent PE, major bleeding, intracranial hemorrhage, and postthrombotic sequelae. We searched the Cochrane Central Register of Controlled Trials, MEDLINE, and Embase for eligible studies, reference lists of relevant reviews, registered trials, and relevant conference proceedings. We included 22 studies with 15 865 patients. Among patients who were diagnosed with PE and discharged with anticoagulation, 3-month follow-up revealed that all-cause mortality was 5.69% (91/1599; 95% confidence interval [CI], 4.56-6.83), mortality from PE was 1.19% (19/1597; 95% CI, 0.66-1.72), recurrent venous thromboembolism (VTE) occurred in 1.38% (22/1597; 95% CI: 0.81-1.95), and major bleeding occurred in 0.90% (2/221%; 95% CI, 0-2.15). In patients with a low pretest probability (PTP) and negative D-dimer, 3-month follow-up revealed mortality from PE was 0% (0/808) and incidence of VTE was 0.37% (4/1094; 95% CI: 0.007-0.72). In patients with intermediate PTP and negative D-dimer, 3-month follow-up revealed that mortality from PE was 0% (0/2747) and incidence of VTE was 0.46% (14/3015; 95% CI: 0.22-0.71). In patients with high PTP and negative computed tomography (CT) scan, 3-month follow-up revealed mortality from PE was 0% (0/651) and incidence of VTE was 0.84% (11/1302; 95% CI: 0.35-1.34). We further summarize outcomes evaluated by various diagnostic tests and diagnostic pathways (ie, D-dimer followed by CT scan).

hematology
Multidisciplinary Approach to Pulmonary Embolism and the Role of the Pulmonary Embolism Response Team

Afaq Motiwala,Hira Tanwir,Alexander Duarte,Syed Gilani,Abe DeAnda,Mohammed Fathi Zaidan,Hani Jneid

DOI: https://doi.org/10.1007/s11886-024-02084-9

Abstract:Purpose of review: Acute pulmonary embolism (PE) is a leading cause of cardiovascular death and morbidity, and presents a major burden to healthcare systems. The field has seen rapid growth with development of innovative clot reduction technologies, as well as ongoing multicenter trials that may completely revolutionize care of PE patients. However, current paucity of robust clinical trials and guidelines often leave individual physicians managing patients with acute PE in a dilemma. Recent findings: The pulmonary embolism response team (PERT) was developed as a platform to rapidly engage multiple specialists to deliver evidence-based, organized and efficient care and help address some of the gaps in knowledge. Several centers investigating outcomes following implementation of PERT have demonstrated shorter hospital and intensive-care unit stays, lower use of inferior vena cava filters, and in some instances improved mortality. Since the advent of PERT, early findings demonstrate promise with improved outcomes after implementation of PERT. Incorporation of artificial intelligence (AI) into PERT has also shown promise with more streamlined care and reducing response times. Further clinical trials are needed to examine the impact of PERT model on care delivery and clinical outcomes.

Fungal Diseases (Field Manual of Wildlife Diseases)

Clinical analysis of acute pulmonary embolism in 49 cases

Pulmonary embolism: the diagnosis, risk-stratification, treatment and disposition of emergency department patients

Risk Stratification and Management of Intermediate- and High-Risk Pulmonary Embolism

Risk Stratification and Management of Intermediate-Risk Acute Pulmonary Embolism

Decoding Pulmonary Embolism: Pathophysiology, Diagnosis, and Treatment

Acute Pulmonary Embolism: A Review

Presentation, Management and Outcomes of Pediatric Pulmonary Embolus: A Retrospective Review

Patients perceptions of information about risks at cardiac surgery.

Acute Pulmonary Embolism: Evidence, Innovation, and Horizons

The diagnosis of Blastocystis hominis cysts in human faeces.

Comparison of costs of percutaneous transluminal coronary angioplasty and coronary bypass surgery for patients with angina pectoris.

Emergency department diagnosis and management of acute pulmonary embolism

Epidemiology, Etiology, and Pathophysiology of Pulmonary Embolism

The Clinical Analysis and Treatment of Acute Pulmonary Embolism

A Silent Fatal Presentation of Pulmonary Embolism: Reflection and Discussion.

Low Risk Meets High Stakes: Unraveling the Mystery of Low D-dimer Pulmonary Embolism

Pulmonary Embolism: An Update Based on the Revised AWMF-S2k Guideline

Advances in the diagnosis of acute pulmonary embolism

Systematic review and meta-analysis of outcomes in patients with suspected pulmonary embolism

Multidisciplinary Approach to Pulmonary Embolism and the Role of the Pulmonary Embolism Response Team